BioNTech SE

0A3M.IL·IOB
Compare
92.03+2.53 (+2.83%)today
As of Oct 21, 9:57 AM BST · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close89.50
Open91.17
Day range90.8292.03
52-week range79.51123.69
Off day high0.00%
Off 52-week high−25.60%
Volume60.00
Avg. volume (3M)23.95K
Market cap25.31B
EPS (TTM)18.00
Forward P/E5.10
P/E ratio (TTM)5.11
Dividend yield—
Beta (5Y)—
Shares outstanding239.77M
Short interest—
Earnings dateNov 3, 2026
Analyst target—
Profit margin—

Against its peers

Compare in full ›
0A3M.IL ROIV 1877.HK GMAB IOVA IBRX
Market cap 25.31B 25.22B 17.65B 24.02B 6.73B 9.29B
P/E (TTM) 5.1 — — 30.8 — —
Forward P/E 5.1 -20.3 86.2 25.8 -75.9 -54.8
Price/book 1.1 6.0 2.5 3.9 9.1 -8.8
Dividend yield — — — — — —
1-year change −16.59% +94.43% −37.10% +30.58% +591.16% +271.61%
Today +2.83% +0.63% +3.74% +1.48% +4.57% +4.16%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All 0A3M.IL news ›
The National Tribune·Positive

BioNTech MRNA Manufacturing Facility Opens

La Trobe University is now home to one of the world’s leading biopharmaceutical companies, with the official opening of BioNTech’s state-of-the-art, clinical-scale mRNA manufacturing and research facility at the University’s campus in…

Defense World·Positive

Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX – Get Free Report) and MiMedx Group (NASDAQ:MDXG – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends,…

@clin_trials·Negative

BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial

BioPharm International connects biopharmaceutical professionals with scientific and business insights on biopharma R&D, manufacturing & regulatory issues. BioNTech announced October 13, 2026, that the phase 2/3 AHEAD-MERIT trial did not…

The Epoch Times·Negative

BioNTech’s mRNA Cancer Vaccine Falls Short of Goal in Trial

A messenger ribonucleic acid (mRNA) vaccine against cancer failed to meet a primary goal of a late-stage clinical trial, the shot’s manufacturer said on Oct. 13. The experimental vaccine, known as BNT113, fell short of its primary endpoint…

From articles in the 4Search news index.

In the news

52mentions in 30 days
52with it in the headline
Mixedsentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 52 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.